News | Radiation Dose Management | February 23, 2017

National Dose Levels Established for 10 Common Adult CT Examinations

Research team uses ACR CT Dose Index Registry data to develop diagnostic reference levels and achievable doses across patient sizes

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD

February 23, 2017 — Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national dose levels for common adult CT examinations based on patient size. Healthcare facilities can optimize these exam protocols so that dose is commensurate with the size of the patient, avoiding unnecessary radiation exposure.

Results of the two-year study, published online in the journal Radiology, established patient size-based diagnostic reference levels (DRLs) and achievable doses (ADs) for the 10 most common CT head, neck and body examinations.

While the impact of patient size on radiation dose is well established, national DRLs previously provided only one value for each examination based on a standard-size phantom representing an average patient, a single patient size or data averaged across all patient sizes.

For the study, Kalpana M. Kanal, Ph.D., a medical physicist, professor and section chief in diagnostic physics in the Department of Radiology at the University of Washington School of Medicine, Seattle, and colleagues examined actual patient data from the American College of Radiology (ACR) CT Dose Index Registry to develop size-based DRLs that enable healthcare facilities to compare their patient doses with national benchmarks and more effectively optimize CT protocols for the wide range of patient sizes they examine.

“This extensive participation and totally automated complete capture of all patient examinations enabled the development of robust, clinically-based national DRLs and ADs,” Kanal said.

DRLs — benchmarks for radiation protection and optimization in imaging — were first mentioned in 1990 by the International Commission on Radiological Protection, while the concept of ADs was introduced in 1999 by the United Kingdom National Radiation Protection Board to further optimize CT protocols.

Decades later, there are few national recommendations for DRLs and ADs, mainly because a large volume of robust patient data on CT examinations did not exist until the ACR launched its Dose Registry Index in 2011. As of 2016, the ACR registry includes more than 30 million examinations from over 1,500 facilities.

In their research, Kanal and colleagues accessed more than 1.3 million ACR CT Dose Index Registry examinations conducted in 2014 at 538 healthcare facilities throughout the United States, located in primarily metropolitan and suburban areas as well as community hospitals.

For head examinations, researchers used lateral thickness as an indicator of patient size, while water-equivalent diameter was used for neck and body examinations.

Data from the 1.3 million CT exams provided median values, as well as means and 25th and 75th DRL percentiles for CT dose index (CTDIvol), dose-length product (DLP) and size-specific dose estimate (SSDE).

DRLs are typically set at the 75th percentile of the dose distribution from a survey conducted across a broad user base using a specified dose-measurement protocol. ADs are set at the 50th percentile of a dose distribution based on the fact that roughly 50 percent of facilities have already achieved doses at or below this value.

Results demonstrated that the new DRLs are not markedly different from those used in other countries.

The use of DRLs has been shown to reduce the overall dose and the range of doses observed in clinical practice, Kanal said. In terms of using the benchmarks established in their research, she stresses that DRLs should be used to determine if a facility’s dose indexes are unusually high, and are not to be used as target doses.

“Both ADs and DRLs are provided to encourage facilities to optimize dose to a lower level than that indicated by the DRL,” Kanal said. “Image quality must be taken into consideration when using DRLs and ADs to evaluate CT protocols on each scanner to determine if protocols are optimized.”

Ideally, facilities should analyze and compare their median and size-grouped dose indexes with the respective size-based ADs and DRLs. If size-grouped dose indexes are not available, they should compare their overall median indexes with the average DRLs and ADs across all patient sizes.

“DRLs and ADs are not intended to be used for comparisons with dose indexes for individual patients,” Kanal said. “Implementation of DRLs and ADs is most effective if the facility has a system to automatically monitor patient dose indexes so that aggregate results may be evaluated.”

Kanal and colleagues plan to expand their analysis to include high-dose examinations and various scanner configurations and will develop DRLs and ADs for the pediatric population.

Radiologists, radiation oncologists, medical physicists and other radiology professionals are working together to standardize CT protocols.

For more information: www.pubs.rsna.org/journal/radiology

Related Cardiac CT Dose Articles and Videos:

• Radiation Dose Management Trends and Best Practices

• VIDEO: Radiation Dose Monitoring in Medical Imaging

• CT Cancer Risk Poorly Understood by Many Healthcare Providers

•  University of California Study Searches for Consistent CT Dose Best Practices
 

Reference:

Kanal, K.M., Butler, P.F., Sengupta, D., Bhargavan-Chatfield, B., et al. "U.S. Diagnostic Reference Levels and Achievable Doses for 10 Adult CT Examinations," Radiology. Published online Feb. 21, 2017. DOI: 10.1148/radiol.2017161911


Related Content

News | Cardiovascular Clinical Studies

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

Home March 06, 2024
Home
News | Cardiovascular Clinical Studies

February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ...

Home February 26, 2024
Home
News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
Subscribe Now